Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858)

P. V. Kotselyabina; A. B. Balaeva; L. V. Fedorova; S. V. Bogatyrev; N. S. Shorokhov; N. E. Mochkin; A. B. Karabekov; A. M. Nurzhanovna; V. Ya. Mel’nichenko; K. V. Lepik; I. S. Moiseev; V. O. Sarzhevsky; E. A. Demina; V. M. Keimakin; N. B. Mikhailova; A. D. Kulagin

Abstract

Oct 03, 2025 3 2

Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858)

P. V. Kotselyabina ¹ ^* ,

A. B. Balaeva ¹,

L. V. Fedorova ¹,

S. V. Bogatyrev ²,

N. S. Shorokhov ²,

N. E. Mochkin ²,

A. B. Karabekov ³,

A. M. Nurzhanovna ³,

V. Ya. Mel’nichenko ²,

K. V. Lepik ²,

I. S. Moiseev ¹,

V. O. Sarzhevsky ²,

E. A. Demina ²,

V. M. Keimakin ³,

N. B. Mikhailova ¹,

A. D. Kulagin ¹

¹ R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantology, First Saint Petersburg State Medical University Named After I.P. Pavlov, Saint Petersburg, Russia² N.I. Pirogov National Medical Surgical Center, Moscow, Russia³ National Research Oncology Center, Astana, Kazakhstan^* Corresponding Author

Oncology, Nuclear Medicine and Transplantology, 1(Suppl. 1), 2025, onmt_A14

Publication date: Oct 03, 2025

Full Text (PDF)

ABSTRACT

---

KEYWORDS

---

CITATION (Vancouver)

Kotselyabina PV, Balaeva AB, Fedorova LV, Bogatyrev SV, Shorokhov NS, Mochkin NE, et al. Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858). Oncology, Nuclear Medicine and Transplantology. 2025;1(Suppl. 1):onmt_A14.

Show other citation styles Hide other citation styles

APA

Kotselyabina, P. V., Balaeva, A. B., Fedorova, L. V., Bogatyrev, S. V., Shorokhov, N. S., Mochkin, N. E., Karabekov, A. B., Nurzhanovna, A. M., Mel’nichenko, V. Y., Lepik, K. V., Moiseev, I. S., Sarzhevsky, V. O., Demina, E. A., Keimakin, V. M., Mikhailova, N. B., & Kulagin, A. D. (2025). Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858). Oncology, Nuclear Medicine and Transplantology, 1(Suppl. 1), onmt_A14.

Harvard

Kotselyabina, P. V., Balaeva, A. B., Fedorova, L. V., Bogatyrev, S. V., Shorokhov, N. S., Mochkin, N. E., . . . Kulagin, A. D. (2025). Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858). Oncology, Nuclear Medicine and Transplantology, 1(Suppl. 1), onmt_A14.

AMA

Kotselyabina PV, Balaeva AB, Fedorova LV, et al. Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858). Oncology, Nuclear Medicine and Transplantology. 2025;1(Suppl. 1), onmt_A14.

Chicago

Kotselyabina, P. V., A. B. Balaeva, L. V. Fedorova, S. V. Bogatyrev, N. S. Shorokhov, N. E. Mochkin, A. B. Karabekov, A. M. Nurzhanovna, V. Ya. Mel’nichenko, K. V. Lepik, I. S. Moiseev, V. O. Sarzhevsky, E. A. Demina, V. M. Keimakin, N. B. Mikhailova, and A. D. Kulagin. "Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858)". Oncology, Nuclear Medicine and Transplantology 2025 1 no. Suppl. 1 (2025): onmt_A14.

MLA

Kotselyabina, P. V. et al. "Efficacy of PD-1 Inhibitor Maintenance Therapy After Autologous Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Interim Results of a Phase II Clinical Study (NCT06812858)". Oncology, Nuclear Medicine and Transplantology, vol. 1, no. Suppl. 1, 2025, onmt_A14.

REFERENCES

---

LICENSE

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.